Wednesday, March 16, 2016

Alvine Pharmaceuticals Acquired By ImmunogenX

San Carlos-based Alvine Pharmaceuticals, which is developing treatments for celiac disease, has been acquired by ImmunogenX, the two said late Tuesday. Financial terms of the acquisition were not disclosed. ImmunogenX is a developer of biopharmaceuticals for treating autoimmune and gastrointestinal diseases, including celiac disease. Alivine's technology is based on research out of Stanford University, and and was backed by Abbott Biotech Ventures, Interwest Partners, Panorama Capital, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.